Research Opportunity for Patients and Care Partners

By Wilson Disease|2022-06-20T12:33:18+00:00June 20, 2022|Clinical Trials|

Ultragenyx’s Wilson Disease Gene Therapy Program Update

By Wilson Disease|2022-03-11T15:56:24+00:00March 11, 2022|Clinical Trials|

GATEWAY IS NOW ACTIVELY ENROLLING AT 3 US CLINICAL SITES!

By Wilson Disease|2022-03-11T15:59:24+00:00March 10, 2022|Clinical Trials|

Shipping Trientine to India through MAP International

By Wilson Disease|2022-03-10T13:38:40+00:00March 10, 2022|News and Notices|

Ultragenyx Research Opportunities for Patients

By Wilson Disease|2021-08-11T14:13:31+00:00August 10, 2021|Clinical Trials|

Registration and availability of Trientine hydrochloride – Australia

By Wilson Disease|2021-04-22T12:36:59+00:00April 21, 2021|News and Notices|

Registration and availability of Trientine hydrochloride – Canada

By Wilson Disease|2021-04-22T12:34:43+00:00April 19, 2021|News and Notices|

Notice of Medication Discontinuation

By Wilson Disease|2021-03-26T12:59:13+00:00March 15, 2021|News and Notices|

Market Research Survey

By Wilson Disease|2021-03-26T12:59:19+00:00February 20, 2020|News and Notices|